This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

SHAREHOLDER ALERT: Investors With More Than $50,000 In Losses From Investments In Amarin Corporation Plc Are Encouraged To Contact Wolf Haldenstein Before The January 3, 2014 Lead Plaintiff Deadline

Stock quotes in this article: AMRN

The law firm of Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating potential federal securities claims against Amarin Corporation plc (“Amarin” or the “Company”) and certain of its officers and directors in connection with allegations that the Company made materially false and misleading statements regarding prospective FDA approval of the proposed “ANCHOR” indication for the Company’s Vascepa drug.

On October 16, 2013, the NASD halted trading in Amarin common stock while the FDA’s Endocrinologic and Metabolic Drugs Advisory Committee considered results of the ANCHOR study, which questioned the drug’s efficacy in treating severe cardiovascular events, and voted 9-2 to reject the New Drug Application for the ANCHOR indication of Vascepa.

On this news, and upon resumption of trading on October 17, 2013, Amarin common stock declined over 60% from $5.17 per share to $2.01 per share on heavy trading volume.

Wolf Haldenstein has represented individual and institutional investors for many years, serving as lead counsel in numerous cases in United States federal and state courts. Please visit the Wolf Haldenstein website ( http://www.whafh.com) for more information about the firm.

Please contact us no later than January 3, 2014 if you own Amarin securities and wish to discuss this matter with us, or have any questions concerning your rights and interests:

Gregory M. Nespole, Esq.Wolf Haldenstein Adler Freeman & Herz LLP270 Madison AvenueNew York, New York 10016

Phone Numbers:(800) 575-0735(212) 545-4657(917) 515-6161

Email: Classmember@whafh.com or nespole@whafh.com and please reference “Amarin Investigation.”

Attorney Advertising

Copyright Business Wire 2010

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,757.63 -47.08 -0.28%
S&P 500 1,943.52 -2.64 -0.14%
NASDAQ 4,417.2030 -4.8820 -0.11%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs